A5072796310- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Lipid metabolism and disorders
- Cholesterol and Lipid Metabolism
- Metabolomics and Mass Spectrometry Studies
- Fatty Acid Research and Health
- Pharmaceutical Economics and Policy
- Liver Disease Diagnosis and Treatment
- Atherosclerosis and Cardiovascular Diseases
- Health and Medical Research Impacts
- Diet and metabolism studies
- Diet, Metabolism, and Disease
- Cardiovascular Disease and Adiposity
- Primary Care and Health Outcomes
- Diabetes Treatment and Management
- Adipokines, Inflammation, and Metabolic Diseases
- Blood Pressure and Hypertension Studies
- Peroxisome Proliferator-Activated Receptors
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Folate and B Vitamins Research
- Cardiovascular Health and Disease Prevention
- Cerebrovascular and Carotid Artery Diseases
Royal Prince Alfred Hospital
2016-2025
National Health and Medical Research Council
2009-2025
The University of Sydney
2016-2025
New South Wales Department of Health
2021-2024
Sydney Local Health District
2023
Institute of Genetics and Cancer
2022
Medical Research Council
2022
University of Edinburgh
2022
Auckland City Hospital
2013-2016
Monash University
2013-2016
In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk events, but effects on mortality from overall have remained uncertain.In double-blind, randomized trial, we compared pravastatin (40 mg daily) those placebo over mean follow-up period 6.1 years in 9014 who were 31 to 75 age. The had history myocardial infarction or hospitalization for unstable angina initial plasma total levels 155 271 per deciliter. Both groups...
An estimated 10% to 20% of patients cannot tolerate statins or adequate doses achieve treatment goals. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein (LDL) receptors, promoting their degradation and increasing LDL cholesterol levels. In phase 1 studies, a human monoclonal antibody PCSK9, AMG145, was well tolerated reduced levels.To assess the efficacy tolerability AMG145 in with statin intolerance due muscle-related side effects.A 12-week,...
Background: Clinical lipid measurements do not show the full complexity of altered metabolism associated with diabetes mellitus or cardiovascular disease. Lipidomics enables assessment hundreds species as potential markers for disease risk. Methods: Plasma (310) were measured by a targeted lipidomic analysis liquid chromatography electrospray ionization–tandem mass spectrometry on case-cohort (n=3779) subset from ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax Diamicron-MR...
Abstract Aims Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially death. As phospholipids also linked with CVD risk, we investigated whether combination of ceramides phosphatidylcholines (PCs) would be synergistic in prediction events patients atherosclerotic coronary heart three independent cohort studies. Methods and results Ceramides PCs were analysed using liquid chromatography–mass spectrometry (LC-MS) studies: WECAC (The...
Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 studies of 12 weeks' duration. The longer-term efficacy and safety PCSK9 inhibition remain undefined.Of 1359 randomized dosed patients the 4 evolocumab parent studies, 1104 (81%) elected to enroll into Open-Label Study Long-term Evaluation Against LDL-C (OSLER) study. Regardless their treatment assignment...
Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference therapy that targets angiopoietin-like protein 3 (ANGPTL3), a regulator of metabolism. This first-in-human, phase 1, randomized, placebo-controlled, open-label trial investigated single repeat doses in four cohorts fifty-two healthy participants one cohort nine with hepatic steatosis, part basket trial. Safety...
Background — The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) events 9014 patients known CHD total cholesterol 4.0 to 7.0 mmol/L at baseline. Secondary objectives included assessment of event reduction according lipid levels. Methods Results We investigated the relationships baseline on-study lipids subsequent separate Cox models. Treatment effect on was examined by after...
Twenty male patients with primary hypertriglyceridemia were treated for 4 weeks daily supplements (15 g) of oil, which provided approximately 6 g polyunsaturated fatty acid (PUFA) either fish or vegetable origin. Total plasma cholesterol concentrations unaffected, but both types supplement increased high density lipoprotein-3 (HDL3) concentrations. The fish, not the vegetable, oil led to a decrease in triglyceride Very low lipoprotein (VLDL), composition, and VLDL kinetics subsequently...
OBJECTIVE People with diabetes frequently develop vascular disease. We investigated the relationship between blood 25-hydroxyvitamin D (25OH-D) concentration and disease risk in type 2 diabetes. RESEARCH DESIGN AND METHODS The relationships 25OH-D at baseline incidence of macrovascular (including myocardial infarction stroke) microvascular (retinopathy, nephropathy, neuropathy, amputation) were analyzed Cox proportional hazards models logistic regression an observational study patients...